APRI Apricus Biosciences, Inc.

2.29
+0  (1%)
Previous Close 2.26
Open 2.24
Price To book 0.00
Market Cap 17.73M
Shares 7,741,000
Volume 48,605
Short Ratio 1.31
Av. Daily Volume 1,384,990

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

NDA resubmission planned for 3Q 2017.
Vitaros
Erectile dysfunction
Phase 2b planned - seeking partnership
RayVa
Secondary Raynaud's Phenomenon

Latest News

  1. Apricus Biosciences, Inc. :APRI-US: Earnings Analysis: Q4, 2016 By the Numbers : March 20, 2017
  2. APRICUS BIOSCIENCES, INC. Financials
  3. Apricus reports 4Q loss
  4. Apricus reports 4Q loss
  5. Apricus Biosciences Provides Corporate Update, Fourth Quarter and Full Year 2016 Financial Results
  6. APRICUS BIOSCIENCES, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and
  7. Apricus Biosciences Provides Corporate Update, Fourth Quarter and Full Year 2016 Financial Results
  8. Q4 2016 Apricus Biosciences Inc Earnings Release - 4:01 pm ET
  9. Apricus Biosciences Sells ED Therapy Rights
  10. Apricus Biosciences Announces Corporate Update, Fourth Quarter and Full Year 2016 Financial Results Conference Call
  11. Apricus Biosciences Announces Corporate Update, Fourth Quarter and Full Year 2016 Financial Results Conference Call
  12. APRICUS BIOSCIENCES, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Termination of a Material D
  13. Apricus Biosciences Announces Sale of Ex-U.S. Vitaros Assets and Rights to Ferring Pharmaceuticals
  14. Apricus Biosciences Announces Sale of Ex-U.S. Vitaros Assets and Rights to Ferring Pharmaceuticals
  15. APRICUS BIOSCIENCES, INC. Files SEC form 8-K, Other Events
  16. Apricus Biosciences Receives Positive Nasdaq Listing Determination
  17. Apricus Biosciences Receives Positive Nasdaq Listing Determination
  18. Apricus Biosciences to Present at the 19th Annual BIO CEO & Investor Conference
  19. Apricus Biosciences to Present at the 19th Annual BIO CEO & Investor Conference
  20. Thursday’s Top Biopharma Movers